RxDoctor Payments Data

Matthew Herrmann, MD

Internal Medicine · Los Angeles, CANPI 1760918551

Payments from drug & device makers

$402,273in general payments, 2019–2025

Across 597 payments — averaging $673.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$394K
  • Gilead$7K
  • EMD Serono, Inc.$706
  • Antares Pharma, Inc.$197
  • Merck$154
  • Exact Sciences$65
  • plus $281 from 9 others

What the payments were for

  • Consulting fees$46,83612%
  • Speaking & faculty fees$263,50069%
  • Travel & lodging$56,69215%
  • Food & beverage$17,0654%
  • Education$1540%
  • Gifts$1760%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$402,273 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$43,861
Medicare patients
113
Services billed
719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala489$1,924,705
DovatoDolutegravir Sodium/Lamivudine277$857,817
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf113$528,472
CabenuvaCabotegravir/Rilpivirine82$526,341
RukobiaFostemsavir Tromethamine59$501,194
TivicayDolutegravir Sodium172$389,833
JulucaDolutegravir/Rilpivirine107$385,104
PrezcobixDarunavir/Cobicistat98$229,444
SerostimSomatropin14$181,149
Egrifta SvTesamorelin Acetate22$153,877
OdefseyEmtricitab/Rilpiviri/Tenof Ala44$151,630
TriumeqAbacavir/Dolutegravir/Lamivudi38$149,469
DescovyEmtricitabine/Tenofov Alafenam60$131,410
OzempicSemaglutide124$115,795
GenvoyaElviteg/Cob/Emtri/Tenof Alafen24$100,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Cabenuva, Rukobia, Tivicay, Juluca$393,899$2,809,757735 claims
GileadBiktarvy, Descovy, Genvoya$6,971$2,156,454573 claims
Johnson & JohnsonPrezcobix, Xarelto$15$242,374122 claims
EMD Serono, Inc.Serostim$706$181,14914 claims
Theratechnologies Inc.Egrifta Sv$27$153,87722 claims
PfizerEliquis, Abrysvo, Premarin$21$42,74693 claims
MerckIsentress$154$38,55021 claims
GSKTrelegy Ellipta, Breo Ellipta$35$15,23827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →